CPSS-Mol score
| Score points . | Genetic risk group∗ . | Bone marrow blasts . | WBC count . | Red blood cell transfusion dependency . |
|---|---|---|---|---|
| 0 | Low | <5% | <13 × 109/L | No |
| 1 | Intermediate-1 | ≥5% | ≥13 × 109/L | Yes |
| 2 | Intermediate-2 | — | — | — |
| 3 | High | — | — | — |
| Score points . | Genetic risk group∗ . | Bone marrow blasts . | WBC count . | Red blood cell transfusion dependency . |
|---|---|---|---|---|
| 0 | Low | <5% | <13 × 109/L | No |
| 1 | Intermediate-1 | ≥5% | ≥13 × 109/L | Yes |
| 2 | Intermediate-2 | — | — | — |
| 3 | High | — | — | — |
| CPSS-Mol risk group category . | |||
|---|---|---|---|
| Total score points . | CPSS-Mol risk group . | Median overall survival,† mo . | Cumulative incidence of transformation to AML at 48 mo,† % . |
| 0 | Low | Not reached | 0 |
| 1 | Intermediate-1 | 64-68 | 3 (8) |
| 2-3 | Intermediate-2 | 30-37 | 21 (24) |
| ≥4 | High | 17-18 | 48 (52) |
| CPSS-Mol risk group category . | |||
|---|---|---|---|
| Total score points . | CPSS-Mol risk group . | Median overall survival,† mo . | Cumulative incidence of transformation to AML at 48 mo,† % . |
| 0 | Low | Not reached | 0 |
| 1 | Intermediate-1 | 64-68 | 3 (8) |
| 2-3 | Intermediate-2 | 30-37 | 21 (24) |
| ≥4 | High | 17-18 | 48 (52) |